P23 acts as a negative regulator of ferroptosis in NSCLC by blocking GPX4 degradation via chaperone-mediated autophagy
By: Chen, Junlin, Peng, Yulin, Zhou, Meirong, Che, Yilin, Zhao, Shilei, He, Chengjian, Zhang, Wen, Tian, Xiangge, Zhang, Wenhao, Liu, Zhe, Zhou, Minghao, Liang, Guobiao, Huo, Xiaokui, Wang, Yan, Yu, Zhenlong, Ma, Xiaochi

BioMed Central
2025-10-02; doi: 10.1186/s12943-025-02439-y

Abstract

Ferroptosis has been identified as a tumor-inhibiting event in a variety of cancers; however, its molecular basis in non-small cell lung cancer (NSCLC) has not been completely elucidated. Notably, glutathione peroxidase 4 (GPX4) plays a crucial role in ferroptosis. Our previous research revealed that prostaglandin E synthase 3 (p23), a potential transcription factor, plays a crucial role in promoting cancer progression and metastasis through succinylation. Our study revealed a previously unknown antiferroptotic function of p23. Mechanistically, p23 stabilizes GPX4 by competitively binding heat shock cognate 71 kDa protein (HSC70) to suppress chaperone-mediated autophagy (CMA) activity, which subsequently inhibits ferroptosis and accelerates tumor growth. Notably, impairing p23 succinylation disrupts its interaction with HSC70, restoring CMA-mediated GPX4 degradation. Collectively, our findings suggest that targeting p23-regulated CMA pathways represents a potentially viable strategy to modulate ferroptosis in NSCLC.

Graphical Abstract

The role of p23 in competing with GPX4 for binding to HSC70, blocking CMA-mediated degradation of GPX4 and inhibiting ferroptosis





Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements